UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016414
Receipt number R000018981
Scientific Title Effect of tapentadol for the cancer pain
Date of disclosure of the study information 2015/02/02
Last modified on 2015/02/02 12:35:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of tapentadol for the cancer pain

Acronym

tapentadol for the cancer pain

Scientific Title

Effect of tapentadol for the cancer pain

Scientific Title:Acronym

tapentadol for the cancer pain

Region

Japan


Condition

Condition

cancer patients

Classification by specialty

Hematology and clinical oncology Adult

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To study of effectiveness and safety of tapentadol for the neuropathic pain or nociceptive pain in cancer patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

Comparison of pain NRS scores between neuropathic pain and nociceptive pain

Key secondary outcomes

Comparison of tapentadol doses between neuropathic pain or nociceptive pain


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

tapentadol

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

cancer patients with cancer related pain with four or more NRS score of pain

Key exclusion criteria

1) bad controlled liver, kidney, heart, lung , hypertension and infectious diseases
2) psychiatric diseases including depression
3) pregnancy or breast-feeding
4) intake of SNRI inhibitor
5) the cases whom the doctor decide not to be the indication

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuo Hirayama

Organization

Higashi Sapporo Hospital

Division name

Department of Hematology Oncology

Zip code


Address

Shiroishiku Higashisapporo 3-3, Sapporo

TEL

011-812-2311

Email

hirayama@hsh.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yasuo Hirayama

Organization

Higashi Sapporo Hospital

Division name

Department of Hematology Oncology

Zip code


Address

Shiroishiku Higashisapporo 3-3, Sapporo

TEL

011-812-2311

Homepage URL


Email

hirayama@hsh.or.jp


Sponsor or person

Institute

Higashi Sapporo Hospital

Institute

Department

Personal name



Funding Source

Organization

Higashi Sapporo Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 02 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2015 Year 01 Month 27 Day

Date of IRB


Anticipated trial start date

2015 Year 02 Month 02 Day

Last follow-up date

2015 Year 09 Month 30 Day

Date of closure to data entry

2015 Year 09 Month 30 Day

Date trial data considered complete

2015 Year 10 Month 10 Day

Date analysis concluded

2015 Year 11 Month 20 Day


Other

Other related information

If the patients number was below the 80, we can prolong the duration of the study.


Management information

Registered date

2015 Year 02 Month 02 Day

Last modified on

2015 Year 02 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018981


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name